Drug intelligence / Profile preview

tetrocarcin-A

Development stage: Unknown
Lead developer: Kyowa Hakko Kogyo
Modality: Small Molecules
Administration: Intraperitoneal, Intravenous

Overview

Tetrocarcin-A is a natural spirotetronate antibiotic isolated from *Micromonospora chalcea* with potent antitumor and antibacterial activities. It acts as an inhibitor of the anti-apoptotic function of Bcl-2 (B-cell lymphoma 2). Additionally, tetrocarcin-A has been shown to downregulate junctional adhesion molecule-A (JAM-A), estrogen receptor alpha (ERα), human epidermal growth factor receptor 2 (HER2), and inhibitor of apoptosis proteins (IAPs). It induces caspase-dependent apoptosis and suppresses tumor cell growth in various preclinical models, including breast and lung cancers.

Other names: TC-Atetrocarcin A

Targets

JAM-A (Junctional adhesion molecule A)BCL-2 (BCL-2 family)ERBB2 (Erb-b2 receptor tyrosine kinase 2)

Beyond the preview

Go deeper on tetrocarcin-A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on tetrocarcin-A.

Explore the full profile